David Lowe

Managing Director, AllosteRx Capital

Role: Associate

Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Stream: Advanced Therapies

Dr David G Lowe is an investor and co-founder of Delta TpX Inc., where he is Chairman and CEO. Delta is developing a new targeted cancer therapy for patients with tumors harboring a specific gene deletion. In his role as seed stage investor and company builder David was also an investor, advisor, and Vice Chair of the Board at Shattuck Labs Inc., (NASDAQ: STTK) developing novel fusions proteins for cancer and inflammatory diseases.

David is also a Co-Founder and Managing Director of AllosteRx Capital, an early-stage venture capital firm. AllosteRx plans to invest in the huge wealth of life sciences opportunities originating from “under-ventured” regions and institutions. Prior to AllosteRx, he served as co-founder and CEO of Austin TX based Aeglea BioTherapeutics (NASDAQ: AGLE). Work at Aeglea generated clinical proof of concept and IPO financing in less than 2.5 years from start up. The Aeglea pipeline is in enzyme replacement therapy for genetic rare diseases and initially also included targeting tumor metabolism for cancer treatment.

Before moving to Austin TX to co-found Aeglea David lived in the San Francisco Bay area where he was a Kauffman Fellow (Class 7) and Managing Director at Skyline Ventures, a healthcare Venture Capital firm with $800M under management. During his 10-year tenure there, David actively evaluated and mentored hundreds of life science companies. A sample of his Skyline investments includes: Novacardia (Acquired by Merck), Avidia (Acquired by Amgen), Dicerna Pharmaceuticals (Acquired by Novo), and Sutro Biopharma (NASDAQ: STRO).

David started his career at Genentech Inc., where he was an accomplished scientist and research Director working across a broad array of disciplines for drug discovery. He was responsible for small molecule and protein drug discovery programs that delivered seven product candidates to the clinic, two of which became marketed products. David holds PhD and BSc degrees in biochemistry from the University of Toronto where he was a National Cancer Institute of Canada Predoctoral Fellow.